Printer Friendly

DEPRENYL USA'S EXPERIMENTAL DRUG HAS POTENTIAL AS 'TREATMENT OF CHOICE' FOR SKIN CANCERS, SAYS PRESIDENT; NAME CHANGED TO DUSA PHARMACEUTICALS

 TORONTO, May 26 /PRNewswire/ -- Dr. Geoffrey Shulman, president and chief executive officer of Deprenyl USA, Inc. (NASDAQ-NMS: DUSA), today told shareholders attending the company's first annual meeting here that the company's experimental cancer treatment involving photodynamic therapy (PDT) "has the potential to become the PDT treatment of choice for certain types of skin cancer, other skin diseases and possibly certain internal conditions."
 Shulman said this is because the company's compound already has been used successfully in numerous pilot studies on human skin cancers, initially at Queen's University at Kingston, Ontario, and recently by many other investigators in North America and Europe. This has lead to greatly increased interest from the scientific community.
 Photodynamic therapy is an emerging medical technique for treating cancers and other diseases using a light-sensitive drug followed by exposure to an intense visible light. Separately, the drug and light have no effect, but when combined, they destroy the targeted cancerous tissue with minimal damage to normal surrounding tissues.
 The company's compound, 5-Aminolevulinic Acid (ALA), is a naturally occurring compound that concentrates preferentially in rapidly growing cells, such as those affected by cancer, where it is converted to a substance sensitive to light.
 Shulman explained that cancerous tissue is traditionally treated by surgery, radiation or chemotherapy, each of which has limitations and side effects. But ALA PDT, unlike surgery, is generally non-invasive and more selective, and unlike radiation and chemotherapy, its side effects are relatively harmless, according to Dr. Shulman, himself a dermatologist.
 Shulman told the audience that the watershed event of the past year was the filing in December of the company's first Investigational New Drug application with the United States Food and Drug Administration. This allowed the company to commence controlled clinical trials, which were begun in February 1993.
 The initial focus of DUSA's development effort is in dermatology, Shulman said. While this first filing with the FDA was for permission to conduct trials on precancerous actinic keratoses and psoriasis, further clinical trials targeting basal cell carcinomas, warts and other skin conditions are planned.
 Research by various investigators also has demonstrated potential for ALA PDT in the treatment of a variety of internal conditions, according to Shulman. One of the most promising, he said, is the use of ALA PDT as an alternative to hysterectomy for women with excessive uterine bleeding. He also said the company signed an option agreement with Queen's University on a series of compounds with potential for use in certain internal cancers where ALA would not be appropriate.
 A method of use patent was granted for ALA PDT in the United States in January 1992, and in Australia in October 1992. Patents are pending in certain other countries, and the company has filed further patent applications during the year, according to Shulman, "to strengthen our proprietary positioning with respect to ALA PDT."
 At the meeting, shareholders approved a change in the company's name to DUSA Pharmaceuticals, Inc. to end confusion with its parent company, Deprenyl Research Limited. The company will retain its stock exchange symbols of DUSA on NASDAQ and DPU on the Toronto Stock Exchange.
 Other significant corporate developments that Shulman recited at the meeting began with the company's successful initial public offering of its common stock in January of 1992. More than $15 million was raised. This was followed by the listing of the company's shares on the NASDAQ and Toronto stock exchanges, the opening of offices in New Jersey, the addition of staff and consultants, strengthening the Board of Directors, developing a new investment banking relationship and initiating an investor relations program.
 "In 1993, DUSA Pharmaceuticals expects to continue progress in its dermatological development program while providing limited funding in the area of internal ALA PDT research, which may have even greater potential in the long run," Dr. Shulman concluded.
 -0- 5/26/93
 /CONTACT: D. Geoffrey Shulman, M.D., president & CEO, in Toronto, 416-537-1070, 416-537-4372, or fax: 416-537-1653 or Joseph P. Castelli, vice president, 201-299-9070, or fax: 201-335-0372, both of Deprenyl USA; or Jim Tolan, senior vice president of O'Connor Biro & Associates, 708-498-2284 or fax: 708-498-3144, for Deprenyl USA/
 (DUSA)


CO: Deprenyl USA, Inc. ST: Ontario IN: MTC SU:

WB -- NY046 -- 2479 05/26/93 13:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 26, 1993
Words:700
Previous Article:ICN WINS AGAIN IN SUIT AGAINST KHAN
Next Article:CORPORATE DEBT REFINANCING ACTIVITIES MAY EXPLAIN MODEST ECONOMIC PACE, SIA SAYS
Topics:


Related Articles
DEPRENYL USA REPORTS RESULTS FOR SECOND QUARTER AND SIX MONTHS ENDING JUNE 30, 1992
DEPRENYL USA, INC. SIGNS AGREEMENT ON ADDITIONAL PHOTODYNAMIC CANCER FIGHTING COMPOUNDS
DEPRENYL USA, INC. REPORTS RESULTS FOR THE THREE AND NINE MONTHS ENDED SEPT. 30, 1992; EXPECTS TO FILE ITS FIRST INVESTIGATIONAL NEW DRUG
DEPRENYL USA REPORTS POSITIVE INDEPENDENT STUDY OF ITS PROPOSED TREATMENT FOR SKIN CANCERS AND OTHER DERMATOLOGICAL DISORDERS
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA COMMENCES INITIAL CONTROLLED HUMAN CLINICAL TRIALS
DEPRENYL USA REPORTS YEAR END 1992 RESULTS; CONFIRMS ALA PHOTODYNAMIC DEVELOPMENT ON SCHEDULE; PROPOSES NAME CHANGE TO DUSA PHARMACEUTICALS
DEPRENYL USA, INC. RECEIVES NEW PATENTS
DEPRENYL USA REPORTS FIRST QUARTER RESULTS ON PLAN INITIAL CLINICAL TRIALS PROCEEDING ON SCHEDULE
DEPRENYL USA INC. GRANTS MEDICIS RIGHT TO FIRST REFUSAL TO MARKET IN THE U.S.; POTENTIAL BREAKTHROUGH DRUG FOR SKIN CANCER, PSORIASIS, AND WARTS

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters